A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.

Inclusion Criteria: 1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study; 2. Patients with unresectable recurrent or metastatic solid tumors; 3. There is at least one lesion could be measured; 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 5. Adequate organ functions as defined; 6. Life expectancy ≥3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases; 2. Subjects who had other malignancy in five years before the first dose; 3. Patients with tumor-related pain that cannot be controlled as determined; 4. Patients with serious cardiovascular and cerebrovascular diseases; 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion; 6. Patients with Severe infections; 7. History of immunodeficiency; 8. History of autoimmune diseases; 9. Unresolved CTCAE Grade \>1 toxicity attributed to any prior anti-tumor therapy 10. Active infection; 11. Pregnant or nursing women; 12. Known history of serious allergic reactions to the investigational product or its main ingredients.